DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20174771

Evaluation of locomotor activity of pioglitazone in albino mice

Shruthi S. L., Kalabharathi H. L., Jayanthi M. K.

Abstract


Background: Pioglitazone (PIO), a Peroxisome Proliferator Activated Receptor γ (PPAR-γ) agonist, is an oral anti-diabetic agent belonging to the group of thiazolidinediones-TZDs used for the treatment of diabetes mellitus type 2 in monotherapy and in combination with a sulfonylurea, metformin, or insulin.

Methods: All animals were allowed to acclimatize with laboratory conditions at least two weeks before starting the experiment and they were maintained under the same condition throughout the experiment. They were given food and water ad libitum. The experiments were performed as per the Committee for the Purpose of Control and Supervision on Experiments on Animals (CPCSEA) guidelines. The animals were subjected to experimentation between 0900-1600 hours in noise free atmosphere with ambient temperature 23-300ºC.

Results: There was no significant reduction in the within group comparisons of the basal and final scores in locomotor activity.

Conclusions: The standard and test groups failed to produce any significant reduction in locomotor activity in the intergroup comparison as well as compared to normal control.


Keywords


Locomotor activity, Mice, Pioglitazone

Full Text:

PDF

References


Barclay LL, Kheyfets S, Zemcov A, Blass JP, McDowell FH. Risk Factors in Alzheimer’s disease. Advances in Behavioral Biology. 1986;29:141-6.

Keith A. Wollen. Alzheimer’s disease: The Pros and Cons of Pharmaceutical, Nutritional, Botanical and Stimulatory Therapies, with a Discussion of Treatment Strategies from the Perspective of Patients and Practitioners. Alternative Medicine Review. 2003;15(3):223-44.

Allan BD, Pocernich CB. The Glutamatergic System and Alzheimer’s Disease Therapeutic Implications. CNS Drugs. 2003;17(9):641-52.

Götz J, Ittner LM. Animal models of Alzheimer’s disease and frontotemporal dementia. Nature review-Neuroscience. 2008;9:532-44.

Colombres M, Sagal JP, Inestrosa NC. An overview of the current and novel drugs for Alzheimer’s disease with particular reference to anti-cholinesterase compounds. Current Pharmaceutical Design. 2004;10(1):3121-30.

Almasi-Nasrabadia M, Javadi-Paydara M, Mahdaviana S, Babaeia R. Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Behavioural Brain Research. 2012;231(1):138-45.

Segovia G, Porras A, Del Arco A, Mora F. Glutamatergic neurotransmission in aging: Acritical perspective. Mech Ageing Dev. 2001;122(1):1-29.

Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306:821-7.

Murali DP. Non- cholinergic strategies for treating and preventing Alzheimer’s disease. CNS Drugs. 2002; 16(12); 811- 824.

Wischer S, Paulus W, Sommer M, Tergau F. Piracetam affects facilitatory I-wave interaction in the human motor cortex. Clin Neurophysiol. 2001;112(2):275-9.

Pilch H, Müller WE. Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology (Berl). 1988;94(1):74-8.

Pathan AR, Viswanad B, Sonkusare SK, Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 2006;79:2209-16.